|
||||||||||||||||||||||
 |
 |
|||||||||||||||||||||
University of Iowa News Release
|
||||||||||||||||||||||
|
Sept. 30, 2011 UI awarded $5.8 million grant for pediatric migraine study The National Institutes of Health has awarded the Clinical Trials Statistical and Data Management Center (CTSDMC) in the University of Iowa College of Public Health a five-year, $5.8 million grant to help study migraine in children and adolescents between 8 and 17 years of age. The CTSDMC will serve as the data coordinating center for the study that compares amitriptyline and topiramate, two medications often used to treat migraine in adults but which have yet to be proven effective for use in children.
Migraine affects more than six million children and adolescents in the United States, according to the Headache Center at Cincinnati Children's Hospital, which will collaborate with the UI investigators and serve as the clinical coordinating center for the study. Migraine headaches are extremely painful, and can be accompanied by blurred vision or auras, nausea or vomiting, and even emotional changes such as anxiety if left untreated. "Migraine can have such a severe impact on a child's quality of life," Coffey said. "Our hope with this study is to provide parents with a proven, effective option for treating migraine in their children, an option based upon sound scientific evidence." STORY SOURCE: University of Iowa College of Public Health Office of Communications and External Relations, 4257 Westlawn, Iowa City, Iowa 52242. MEDIA CONTACT: Bill Barker, william-barker@uiowa.edu, 319-384-4277
|
||||||||||||||||||||||
"There are currently no medications approved by the FDA to prevent childhood migraine," said Christopher Coffey, Ph.D., UI professor of biostatistics and director of the CTSDMC. "The results of this study will have worldwide impact on the decisions made by pediatricians, family practitioners, neurologists and other health care professionals dealing with migraine in adolescents."